Monopar Therapeutics, Inc. (MNPR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Monopar Therapeutics, Inc.

Landos Biopharma, Inc.

Cadrenal Therapeutics, Inc.

BioCardia, Inc.

Imunon, Inc.

Brainstorm Cell Therapeutics, Inc.

Organovo Holdings, Inc.

Atreca, Inc.

CohBar, Inc.

Athersys, Inc.

Aravive, Inc.

Why is Monopar Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Monopar Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Monopar Therapeutics, Inc.

51.46%

15.15

87.55%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-214.32%

EBIT to Interest (avg)

-10.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.08%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.90

EV to EBIT

-12.37

EV to EBITDA

-12.37

EV to Capital Employed

-126.30

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-13.73%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

NET PROFIT(HY)

Higher at USD -5.89 MM

ROCE(HY)

Highest at -26.54%

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

CASH AND EQV(HY)

Highest at USD 196.93 MM

-17What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -3.44 MM has Fallen at -163.56%

NET PROFIT(Q)

At USD -3.44 MM has Fallen at -163.56%

OPERATING CASH FLOW(Y)

Lowest at USD -10.83 MM

DEBT-EQUITY RATIO (HY)

Highest at -101.45 %

Here's what is working for Monopar Therapeutics, Inc.

Cash and Eqv

Highest at USD 196.93 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Monopar Therapeutics, Inc.

Pre-Tax Profit

At USD -3.44 MM has Fallen at -163.56%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -3.44 MM has Fallen at -163.56%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -10.83 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Highest at -101.45 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio